Shopping Cart 0
Cart Subtotal
AED 0

Mesoblast Ltd (MSB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Mesoblast Ltd (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft versus host disease; MPC-06-ID, for the treatment of chronic low back pain (CLBP); and MPC-300-IV for the treatment of chronic inflammatory conditions such as biologic-refractory rheumatoid arthritis, and diabetic nephropathy. Mesoblast conducts clinical trials in areas including cardiac diseases, spinal orthopedic disorders, cancer, hematological conditions, and immune-mediated and inflammatory conditions. The company has operational presence in the US and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.

Mesoblast Ltd (MSB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mesoblast Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Mesoblast Acquires Mesenchymal Stem Cell Portfolio From Osiris Therapeutics For Up To USD 100 Million 12

Private Equity 14

Mesoblast Raises USD10 Million in Financing 14

Partnerships 16

Mesoblast Enters into Partnership with Tasly Pharma 16

Mesoblast Enters into Agreement with Cartherics 17

Mesoblast Enters into Agreement with Mallinckrodt Pharma 18

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 19

Licensing Agreements 21

JCR Pharma Enters into Licensing Agreement with Mesoblast 21

Mesoblast Enters into Licensing Agreement with TiGenix 22

Mesoblast Enters into Licensing Agreement with Harvard Medical School 23

Equity Offering 24

Mesoblast Raises USD40 Million in Rights Offering of Shares 24

Mesoblast Plans to Raise up to USD180 Million in Public Offering of American Depositary Shares 26

Mesoblast Raises USD40 Million in Private Placement of Shares 27

Mesoblast to Raise up to USD45 Million in Private Placement of Shares 28

Mesoblast Raises USD68 Million in Public Offering of ADSs 29

Mesoblast Raises USD44.8 Million in Private Placement of Shares 31

Mesoblast Completes Private Placement Of Shares For USD 174 Million 32

Acquisition 33

Teva Pharma Sells Stake in Mesoblast 33

Mesoblast Ltd-Key Competitors 34

Mesoblast Ltd-Key Employees 35

Mesoblast Ltd-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Aug 30, 2018: Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights 37

May 31, 2018: Mesoblast Reports Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018 44

Feb 27, 2018: Mesoblast Announces Financial Results for the Half-Year Ended December 31, 2017 47

Aug 30, 2017: Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 52

Feb 26, 2017: Mesoblast Presents Corporate Update And Financial Results For The Half Year Period Ended December 31, 2016 58

Corporate Communications 62

Jul 11, 2018: Mesoblast Names Shawn Cline Tomasello As Board Director 62

Jun 19, 2018: Mesoblast Names Joseph R. Swedish As Board Director 63

May 30, 2018: Mesoblast Names Josh Muntner As New Chief Financial Officer 64

Product News 65

10/29/2018: JCR to initiate development of TEMCELL HS Inj. (JR-031EB) for the indication of epidermolysis bullosa 65

Product Approvals 66

Mar 07, 2017: FDA Grants Fast Track Designation For Mesoblast's Cell Therapy In Children With Acute Graft Versus Host Disease 66

Clinical Trials 67

Sep 20, 2018: Children treated with remestemcel-l continue to have strong survival outcomes at six months in mesoblast's phase 3 trial for acute graft versus host disease 67

Jun 21, 2018: Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting 68

May 08, 2018: Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting 69

Feb 22, 2018: Primary Endpoint Successfully Achieved in Mesoblast's Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease 70

Dec 20, 2017: Mesoblasts Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment 71

Sep 25, 2017: Mesoblast Presents Update on lead product candidate MSC-100-IV at Global Healthcare Conferences 72

Aug 16, 2017: Positive Trial Results of Mesoblast Cell Therapy in Post-traumatic Osteoarthritis Published in Arthritis Research & Therapy 73

Apr 10, 2017: Successful Interim Analysis of Efficacy Endpoint In Mesoblasts Phase 3 Trial for Chronic Heart Failure 74

Apr 03, 2017: FDA Clears Heart Disease Trial At Harvard's Boston Children's Hospital Using Mesoblast's Cell Therapy In Children With Congenital Heart Disease 75

Mar 31, 2017: Independent Data Monitoring Committee Initiates Process for Interim Analysis of Mesoblasts Phase 3 Chronic Heart Failure Trial 76

Other Significant Developments 77

Dec 07, 2017: Mesoblast Named Global Technology Leader in Cell Therapy Industry 77

Appendix 78

Methodology 78

About GlobalData 78

Contact Us 78

Disclaimer 78


List Of Figure

List of Figures

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Mesoblast Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mesoblast Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mesoblast Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Mesoblast Acquires Mesenchymal Stem Cell Portfolio From Osiris Therapeutics For Up To USD 100 Million 12

Mesoblast Raises USD10 Million in Financing 14

Mesoblast Enters into Partnership with Tasly Pharma 16

Mesoblast Enters into Agreement with Cartherics 17

Mesoblast Enters into Agreement with Mallinckrodt Pharma 18

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 19

JCR Pharma Enters into Licensing Agreement with Mesoblast 21

Mesoblast Enters into Licensing Agreement with TiGenix 22

Mesoblast Enters into Licensing Agreement with Harvard Medical School 23

Mesoblast Raises USD40 Million in Rights Offering of Shares 24

Mesoblast Plans to Raise up to USD180 Million in Public Offering of American Depositary Shares 26

Mesoblast Raises USD40 Million in Private Placement of Shares 27

Mesoblast to Raise up to USD45 Million in Private Placement of Shares 28

Mesoblast Raises USD68 Million in Public Offering of ADSs 29

Mesoblast Raises USD44.8 Million in Private Placement of Shares 31

Mesoblast Completes Private Placement Of Shares For USD 174 Million 32

Teva Pharma Sells Stake in Mesoblast 33

Mesoblast Ltd, Key Competitors 34

Mesoblast Ltd, Key Employees 35

Mesoblast Ltd, Other Locations 36

Mesoblast Ltd, Subsidiaries 36

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Mesoblast Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Mesoblast Ltd (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft versus host disease; MPC-06-ID, for the treatment of chronic low back pain (CLBP); and MPC-300-IV for the treatment of chronic inflammatory conditions such as biologic-refractory rheumatoid arthritis, and diabetic nephropathy. Mesoblast conducts clinical trials in areas including cardiac diseases, spinal orthopedic disorders, cancer, hematological conditions, and immune-mediated and inflammatory conditions. The company has operational presence in the US and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.

Mesoblast Ltd (MSB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mesoblast Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Mesoblast Acquires Mesenchymal Stem Cell Portfolio From Osiris Therapeutics For Up To USD 100 Million 12

Private Equity 14

Mesoblast Raises USD10 Million in Financing 14

Partnerships 16

Mesoblast Enters into Partnership with Tasly Pharma 16

Mesoblast Enters into Agreement with Cartherics 17

Mesoblast Enters into Agreement with Mallinckrodt Pharma 18

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 19

Licensing Agreements 21

JCR Pharma Enters into Licensing Agreement with Mesoblast 21

Mesoblast Enters into Licensing Agreement with TiGenix 22

Mesoblast Enters into Licensing Agreement with Harvard Medical School 23

Equity Offering 24

Mesoblast Raises USD40 Million in Rights Offering of Shares 24

Mesoblast Plans to Raise up to USD180 Million in Public Offering of American Depositary Shares 26

Mesoblast Raises USD40 Million in Private Placement of Shares 27

Mesoblast to Raise up to USD45 Million in Private Placement of Shares 28

Mesoblast Raises USD68 Million in Public Offering of ADSs 29

Mesoblast Raises USD44.8 Million in Private Placement of Shares 31

Mesoblast Completes Private Placement Of Shares For USD 174 Million 32

Acquisition 33

Teva Pharma Sells Stake in Mesoblast 33

Mesoblast Ltd-Key Competitors 34

Mesoblast Ltd-Key Employees 35

Mesoblast Ltd-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Aug 30, 2018: Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights 37

May 31, 2018: Mesoblast Reports Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018 44

Feb 27, 2018: Mesoblast Announces Financial Results for the Half-Year Ended December 31, 2017 47

Aug 30, 2017: Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 52

Feb 26, 2017: Mesoblast Presents Corporate Update And Financial Results For The Half Year Period Ended December 31, 2016 58

Corporate Communications 62

Jul 11, 2018: Mesoblast Names Shawn Cline Tomasello As Board Director 62

Jun 19, 2018: Mesoblast Names Joseph R. Swedish As Board Director 63

May 30, 2018: Mesoblast Names Josh Muntner As New Chief Financial Officer 64

Product News 65

10/29/2018: JCR to initiate development of TEMCELL HS Inj. (JR-031EB) for the indication of epidermolysis bullosa 65

Product Approvals 66

Mar 07, 2017: FDA Grants Fast Track Designation For Mesoblast's Cell Therapy In Children With Acute Graft Versus Host Disease 66

Clinical Trials 67

Sep 20, 2018: Children treated with remestemcel-l continue to have strong survival outcomes at six months in mesoblast's phase 3 trial for acute graft versus host disease 67

Jun 21, 2018: Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting 68

May 08, 2018: Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting 69

Feb 22, 2018: Primary Endpoint Successfully Achieved in Mesoblast's Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease 70

Dec 20, 2017: Mesoblasts Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment 71

Sep 25, 2017: Mesoblast Presents Update on lead product candidate MSC-100-IV at Global Healthcare Conferences 72

Aug 16, 2017: Positive Trial Results of Mesoblast Cell Therapy in Post-traumatic Osteoarthritis Published in Arthritis Research & Therapy 73

Apr 10, 2017: Successful Interim Analysis of Efficacy Endpoint In Mesoblasts Phase 3 Trial for Chronic Heart Failure 74

Apr 03, 2017: FDA Clears Heart Disease Trial At Harvard's Boston Children's Hospital Using Mesoblast's Cell Therapy In Children With Congenital Heart Disease 75

Mar 31, 2017: Independent Data Monitoring Committee Initiates Process for Interim Analysis of Mesoblasts Phase 3 Chronic Heart Failure Trial 76

Other Significant Developments 77

Dec 07, 2017: Mesoblast Named Global Technology Leader in Cell Therapy Industry 77

Appendix 78

Methodology 78

About GlobalData 78

Contact Us 78

Disclaimer 78


List Of Figure

List of Figures

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Mesoblast Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mesoblast Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mesoblast Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Mesoblast Acquires Mesenchymal Stem Cell Portfolio From Osiris Therapeutics For Up To USD 100 Million 12

Mesoblast Raises USD10 Million in Financing 14

Mesoblast Enters into Partnership with Tasly Pharma 16

Mesoblast Enters into Agreement with Cartherics 17

Mesoblast Enters into Agreement with Mallinckrodt Pharma 18

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 19

JCR Pharma Enters into Licensing Agreement with Mesoblast 21

Mesoblast Enters into Licensing Agreement with TiGenix 22

Mesoblast Enters into Licensing Agreement with Harvard Medical School 23

Mesoblast Raises USD40 Million in Rights Offering of Shares 24

Mesoblast Plans to Raise up to USD180 Million in Public Offering of American Depositary Shares 26

Mesoblast Raises USD40 Million in Private Placement of Shares 27

Mesoblast to Raise up to USD45 Million in Private Placement of Shares 28

Mesoblast Raises USD68 Million in Public Offering of ADSs 29

Mesoblast Raises USD44.8 Million in Private Placement of Shares 31

Mesoblast Completes Private Placement Of Shares For USD 174 Million 32

Teva Pharma Sells Stake in Mesoblast 33

Mesoblast Ltd, Key Competitors 34

Mesoblast Ltd, Key Employees 35

Mesoblast Ltd, Other Locations 36

Mesoblast Ltd, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Mesoblast Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.